Jackie Oh SeungJu, Han Songhee, Lee Wooin, Lockhart A Craig
a Department of Philosophy-Neuroscience-Psychology , Washington University in St. Louis , St. Louis , Missouri , USA.
b College of Pharmacy and Research Institute of Pharmaceutical Sciences , Seoul National University , Seoul , Korea.
Expert Opin Investig Drugs. 2016 Jun;25(6):667-77. doi: 10.1517/13543784.2016.1163336. Epub 2016 Mar 24.
Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer.
Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications.
Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.
食管癌是胃肠道第三大常见癌症。尽管有了新的治疗方法，但这些癌症患者的预后仍然很差，5年生存率低于15%。最近，免疫疗法作为晚期食管癌的一种新型治疗策略越来越受到关注。
免疫疗法最近在治疗其他实体瘤方面取得的成功，为这些方法在食管癌治疗中的应用带来了启示。在此，作者重点介绍基于抗体、基于过继性细胞疗法和基于疫苗的免疫疗法，并简要阐述其原理、临床数据及意义。
免疫疗法现已成为一种关键的治疗方式，可改善许多癌症患者的治疗效果，似乎正在开创癌症治疗的新纪元。检查点抑制剂药物在食管癌治疗中已显示出初步的良好效果。过继性细胞疗法和疫苗研究在各种临床研究中也显示出一些前景。未来的努力需要集中在识别可能从免疫疗法中获益的患者、监测和管理免疫反应，以及设计免疫治疗药物与其他传统治疗方式联合的最佳联合策略。
